Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Nine months ended September 30, 2024
Business Overview: A clinical-stage biotechnology company focused on developing therapies for diseases involving innate immune dysfunction. The company operates two primary platforms: the DN-TNF platform (XPro/INB03) targeting Alzheimer's disease, treatment-resistant depression, and cancer; and the Natural Killer Cell Priming platform (INKmune) targeting hematologic malignancies and solid tumors.
Key Financial Metrics
| Metric (in thousands) | 9 Months Ended Sept 30, 2024 | 9 Months Ended Sept 30, 2023 |
|---|---|---|
| Revenue | $14 | $127 |
| Net Loss | $(32,864) | $(21,600) |
| Net Loss Per Share (Basic & Diluted) | $(1.71) | $(1.20) |
| Operating Expenses | $33,182 | $21,489 |
| Research & Development (R&D) | $25,813 | $14,266 |
| General & Administrative (G&A) | $7,369 | $7,223 |
| Cash and Cash Equivalents (Sept 30, 2024) | $33,552 | $35,848 (Dec 31, 2023) |
| Net Cash Used in Operating Activities | $(22,348) | $(8,579) |
| Net Cash Provided by Financing Activities | $20,289 | $(1,725) |
| Current Debt (Principal) | $2,494 | $9,921 (Dec 31, 2023) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $14,000 from $127,000 in the prior year, primarily due to the cessation of sales of mesenchymal stem cells to third parties.
- Increased Net Loss: Net loss widened by $11.3 million (52% increase) to $32.9 million, driven by a $11.5 million increase in operating expenses.
- R&D Expense Surge: R&D expenses increased by $11.5 million (81%) to $25.8 million. This was largely due to accelerated enrollment in the Alzheimer's Phase II clinical trial ($10.3 million increase) and progress in the INKmune prostate cancer trial ($1.8 million increase).
- Debt Reduction: The company repaid $7.5 million of its term loan during the period, reducing the current portion of long-term debt from $9.9 million to $2.5 million.
- Financing Activity: The company raised approximately $27.8 million in gross proceeds through registered direct offerings and At-The-Market (ATM) sales, compared to $0.8 million in the prior year.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With $33.6 million in cash, the company projects insufficient liquidity to sustain operations for one year following the issuance of these financial statements.
- Capital Strategy: The company is evaluating strategies to secure funding, including public or private equity sales, debt financing, government grants, collaborations, or asset divestment. There is no assurance that additional financing will be available on favorable terms.
- Clinical Milestones:
- Alzheimer's (XPro): Enrollment for the Phase II trial in early Alzheimer's disease with biomarkers of inflammation closed in Q3 2024. Top-line data is expected approximately seven months after the last patient enrollment.
- Prostate Cancer (INKmune): The Phase I/II trial in metastatic castration-resistant prostate cancer is ongoing. Enrollment is estimated to complete in the first half of 2025.
- Depression (XPro): The company expects to receive authorization to initiate a Phase II trial for treatment-resistant depression in the second half of 2024.
- Contingencies: An ongoing dispute with a vendor involves approximately $1.2 million in outstanding invoices; the company has recorded only $0.2 million as an obligation, believing the remainder was invoiced erroneously.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next capital raise given the explicit "substantial doubt" regarding going concern status and the projection of insufficient funds for one year.
- Debt Maturity: Confirm the repayment schedule for the remaining $2.5 million term loan, which matures on January 1, 2025, and the associated interest rate (12.5% as of Sept 30, 2024).
- Clinical Trial Costs: Monitor the burn rate associated with the Alzheimer's Phase II trial, which drove the majority of the R&D expense increase.
- Vendor Dispute Resolution: Track the status of the $1.0 million disputed vendor invoice to assess potential future liability.
- Dilution Risk: Review the terms of recent registered direct offerings and the remaining capacity under the amended ATM program ($74.7 million available) to assess potential dilution from future equity raises.